# IAP12 Rec'd PCT/PTO 3 0 APR 2007

	MENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER			
(REV 12-2001)		039371-17			
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)		U.S. APPLICATION NO. (If known, see 37 CFR 1.5)			
CONCERNING A SUBMI	10/581,969				
INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED			
PCT/JP2004/018179	7 December 2004 (07.12.2004)	8 December 2003 (08.12.2003)			
TITLE OF INVENTION					
NOVEL INTERACTION BETWEEN PROTEINS, AND THERAPEUTIC AGENT FOR DISUSE MUSCULAR ATROPHY OR METHOD ASSOCIATED WITH DISUSE MUSCULAR ATROPHY TAKING ADVANTAGE OF NOVEL INTERACTION					
APPLICANT(S) FOR DO/EO/US					
Tohru NATSUME and Ken WATANABE					
other information:	nited States Designated/Elected Office (E	,			
	of items concerning a filing under 35 U.S				
_	SEQUENT submission of items concerning				
	promptly begin national examination prons (5), (6), (9) and (21) indicated below.	cedures (35 U.S.C. 371(f)). The			
4.  The US has been elected (A	ticle 31).				
= -	Application as filed (35 U.S.C. 371(c)(2))				
	ed only if not communicated by the Interr	national Bureau).			
b. has been communicated by	•	oniving Office (PO/HS)			
	plication was filed in the United States Re	•			
a.  is attached hereto.	tion of the International Application as fil	ed (35 U.S.C. 3/1(c)(2)).			
b.  has been previously subn	, , , ,	S.A. (1. 10 (25 M G.G. 251( )/2))			
<ul> <li>7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)).</li> <li>a. are attached hereto (required only if not communicated by the International Bureau).</li> <li>b. have been communicated by the International Bureau.</li> </ul>					
c.  have not been made; how	vever, the time limit for making such ame	ndments has NOT expired.			
8.   An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C.					
371(c)(3)).		G 271( )(A))			
9. An oath or declaration of the inventor(s) (two (2) documents) (35 U.S.C. 371(c)(4)).					
10. An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).					
Items 11 to 20 below concern document(s) or information included:					
11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.					
12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.					
13. A preliminary amendment.					
14. 🗷 An Application Data Sheet under 37 CFR 1.76.					
15. A substitute specification.					
16. A power of attorney and/or of	change of address letter.				
`	17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 -				
18. A second copy of the published International Application under 35 U.S.C. 154(d)(4).					
	h language translation of the International				

U.S. APPLICATION	ON NO. (If known, see 37	C.F.R. 1.50)	INTERNATIONAL	INTERNATIONAL APPLICATION NO		ATTORNEY'S DOCKET NUMBER	
	10/581,969		PCT/JP2004/018179			039371-17	
20. Other items or information: Copy of Notification of Missing Requirements Submission of Sequence Listing and Statement Under 37 CFR 1.821 Sequence Listing Five (5) Non Patent References Return Receipt Postcard							
	The follow	ing fees a	re submitted:		CAL	CULATIONS	PTO USE ONLY
21.  Basic national fee (37 CFR 1.492(a))\$300.00			\$				
22.  Examination fee (37 CFR 1.492(c))				\$			
If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)				:			
22 <b>П</b> Sea	rch fee (27 CEP	1.402(b)	<u> </u>		\$		
23.  Search fee (37 CFR 1.492(b))  If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)				φ			
TOTAL OF 21, 22 and 23 = \$							
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing in compliance with 37 CFR 1.821(c) or (e) or computer program listing filed in an electronic medium) (37 CFR 1.492(j)).  The fee is \$250 for each additional 50 sheets of paper or fraction thereof.							
Total Sheets	Extra sheets			i e			
- 100 =	/50 =			x \$250.00	\$		
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$			
CLAIMS	NUMBER	R FILED	NUMBER EXTRA	RATE			
Total claims		- 20 =		x \$50.00	\$		
Independent cla	ims	- 3 =		x \$200.00	\$		
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$360.00			\$				
TOTAL OF ABOVE CALCULATIONS =				\$			
Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by ½.							
SUBTOTAL =			\$				
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).			\$		····		
TOTAL NATIONAL FEE =			\$				
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +			\$				
TOTAL FEES ENCLOSED =			\$				
					int to be ded:	\$	
						int to be	\$

а. 🗆	A check in the amount of \$ to cover the above fees is	enclosed.		
b. 🗖	Please charge my Deposit Account No in the ar	mount of \$ to cover the above fees.		
c. 🗷	The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-2478 (039371-17).			
d.  Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. The PTO-2038 should only be mailed or faxed to the USPTO. However, when paying the basic national fee, the PTO-2038 may NOT be faxed to the USPTO.				
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.				
	ALL CORRESPONDENCE TO: omer No. 25570	Disposer Venna		
P.O. E	rts Mlotkowski & Hobbes Box 10064 an, VA 22102	Stanislaus Aksman  NAME  28,562  REGISTRATION NUMBER		



### United States Patent and Trademark Office

Verified By

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Dox 1459 Alexandria, Virginia 22313-1450 www.uspto.gov

\*OC000000022611749\*


U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT		ATTY.	DOCKET NO.
10/581,969	Tohru Natsume	039371-1		9371-17
		INTER	NATIONAL APPI	LICATION NO.
			PCT/JP04/1	8179
25570	•	I.A. FIL	ING DATE	PRIORITY DATE
ROBERTS, MLOTKOWSKI & HOBE P. O. BOX 10064	BES	12/0	7/2004	12/08/2003
MCLEAN, VA 22102-8064			CONFIRMA	ATION NO. 8384
	Docketed By acc 03-26-2007	<b>371 FORM</b>	ALITIES LE	ETTER

Date Mailed: 02/26/2007

## NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495).

- Copy of the International Application filed on 06/07/2006
- Copy of the International Search Report filed on 06/07/2006
- Biochemical Sequence Listing filed on 06/07/2006
- Reguest for Immediate Examination filed on 06/07/2006
- U.S. Basic National Fees filed on 06/07/2006
- Priority Documents filed on 06/07/2006



The following items MUST be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.
- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the

sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web. <a href="https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html">https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html</a>

For more information about EFS-Web please call the USPTO Electronic Business Center at **1-866-217-9197** or visit our website at http://www.uspto.gov/ebc.

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

#### FREDERICK SMITH

Telephone: (703) 308-9140 EXT 210

#### PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/581,969	PCT/JP04/18179	039371-17

FORM PCT/DO/EO/905 (371 Formalities Notice)





## Certificate of Mailing under 37 CFR 1.8

I hereby certify that the following listed correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

on <u>April 26, 2007</u>.

Date

Transmittal Letter to the United States Designated/Elected Office
Copy of Notification of Missing Requirements
Declaration and Power of Attorney for Patent Application (2 documents)
Application Data Sheet
Submission of Sequence Listing and Statement Under 37 CFR 1.821
Sequence Listing
Computer Readable Form (CRF) Copy of the Sequence Listing
Information Disclosure Statement with Form PTO-1449 and cited refs. (5 NPL)

Sharon S. Jabar				
Signature				
Sharon L. Tabor				
Typed or printed name of person signing Certificate				
	(703) 677-3001			
Registration Number, if applicable	Telephone Number			

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.